← All organizations
Highest phase reached
Phase 3
First clinical trial
Nov 1, 2015Last known activity
Dec 1, 2025
Timeline
2010s
- Nov 1, 2015
French Innovative Leukemia Organisation— Founded
Drugs by trial phase (67 distinct, 53 trials)
Phase 3 (36 own, 0 via acquisition)
Phase 2 (30 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Aggression
- Hodgkin Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Primary Myelofibrosis
- Recurrence
- Thrombocythemia, Essential
- Thrombocytosis
- Waldenstrom Macroglobulinemia
Recent trials (50)
- NCT07007052Lead sponsorPhase 2Dec 1, 2025
- NCT06547866Lead sponsorPhase 2Oct 1, 2024
- NCT06186648Lead sponsorPhase 2Mar 21, 2024
- NCT06022003Lead sponsorPhase 2Dec 15, 2023
- NCT04992949Overall official - principal investigatorPhase 2Oct 1, 2021
- NCT04992949Lead sponsorPhase 2Oct 1, 2021
- NCT04968015Overall official - principal investigatorPhase 2Sep 15, 2021
- NCT04968015Lead sponsorPhase 2Sep 15, 2021
- NCT04963946Lead sponsorPhase 2Sep 15, 2021
- NCT04963946Overall official - principal investigatorPhase 2Sep 15, 2021
- NCT04010968Lead sponsorPhase 2Sep 30, 2019
- NCT03931642Lead sponsorPhase 2Jun 30, 2019
- NCT03766763Overall official - principal investigatorPhase 2May 22, 2019
- NCT03766763Study chairPhase 2May 22, 2019
- NCT03766763Lead sponsorPhase 2May 22, 2019
Details
- Founded
- Tours, FR Nov 1, 2015
- Last known activity
- Dec 1, 2025